Document:

Rights Agreement Amendment

 Exhibit 4.1 
 RIGHTS AGREEMENT AMENDMENT 
 This Amendment, dated as of July 27, 2009 (the
“Amendment”), to the Rights Agreement, dated as of May 13, 2005, as amended June 7, 2006, as further amended October 3, 2006 (the “Rights Agreement”), is between TorreyPines
Therapeuctis, Inc., a Delaware corporation (the “Company”), and American Stock Transfer and Trust Company (replacing The Nevada Agency and Trust Company) (the “Rights Agent”). 
 The Company and the Rights Agent have heretofore executed and entered into the Rights Agreement. Pursuant to Section 27 of the Rights Agreement, the
Company and the Rights Agent may from time to time supplement or amend the Rights Agreement in accordance with the provisions of Section 27 thereof and the Company desires and directs the Rights Agent to so amend the Rights Agreement.

 In consideration of the foregoing premises and mutual agreements set forth in the Rights Agreement and this Amendment, the parties hereto
agree as follows: 
 1. Section 1(a) of the Rights Agreement, which sets forth the definition of “Acquiring Person,” is hereby
modified and amended to read in its entirety as follows: 
 “(a) “Acquiring Person” shall mean any Person (as
such term is hereinafter defined) who or which, together with all Affiliates (as such term is hereinafter defined) and Associates (as such term is hereinafter defined) of such Person, shall be the Beneficial Owner (as such term is hereinafter
defined) of 15% or more of the shares of Common Stock then outstanding or who was such a Beneficial Owner at any time after the date hereof, whether or not such Person continues to be the Beneficial Owner of 15% or more of the outstanding shares of
Common Stock. Notwithstanding the foregoing, (i) in no event shall a Person who or which, together with all Affiliates and Associates of such Person, is the Beneficial Owner of less than 15% of the Company’s outstanding shares of Common
Stock become an Acquiring Person solely as a result of a reduction of the number of shares of outstanding Common Stock, including repurchases of outstanding shares of Common Stock by the Company, which reduction increases the percentage of
outstanding shares of Common Stock beneficially owned by such Person (provided that any subsequent increase in the amount of Common Stock beneficially owned by such Person, together with all Affiliates and Associates of such Person, without the
prior approval of the Company shall cause such Person to be an Acquiring Person); (ii) the term Acquiring Person shall not mean (A) the Company, (B) any subsidiary of the Company (as such term is hereinafter defined), (C) any
employee benefit plan of the Company or any of its subsidiaries, or (D) any entity holding securities of the Company organized, appointed or established by the Company or any of its subsidiaries for or pursuant to the terms of any such plan;
and (iii) no Person shall be deemed to be an Acquiring Person if (A) within five business days after such Person 

 
would otherwise have become an Acquiring Person (but for the operation of this clause (iii)), such Person notifies the Board of Directors that such Person
did so inadvertently and, within two business days after such notification, such Person is the Beneficial Owner of less than 15% of the outstanding shares of Common Stock, (B) by reason of such Person’s Beneficial Ownership of 15% or more
of the outstanding shares of Common Stock on the date hereof if, prior to the Record Date, such Person notifies the Board of Directors that such Person is no longer the Beneficial Owner of 15% or more of the then outstanding shares of Common Stock
or (C) the Board of Directors determines in good faith that a Person who would otherwise be an Acquiring Person, as defined pursuant to the foregoing provisions of this paragraph (a), has become such inadvertently, and such Person divests
Beneficial Ownership as promptly as practicable of a sufficient number of shares of Common Stock so that such Person would no longer be an Acquiring Person, as defined pursuant to the foregoing provisions of this paragraph (a). In addition,
notwithstanding the foregoing, none of TorreyPines Therapeutics, Inc., a Delaware corporation (“TorreyPines”), or any Affiliate or Associate thereof, or any stockholder of TorreyPines shall become an “Acquiring Person” as a
result of (i) the approval, execution, delivery or performance of that certain Agreement and Plan of Merger and Reorganization dated as of June 7, 2006 (as the same may be amended from time to time, the “Merger Agreement”), by
and among the Company, TorreyPines and Autobahn Acquisition, Inc., including the approval, execution, delivery or performance of any amendments thereto, (ii) the consummation of the Merger (as such term is defined in the Merger Agreement),
(iii) the issuance of Common Stock pursuant to the Merger Agreement, (iv) the announcement of the Merger Agreement or the Merger, or (v) the consummation of any other transaction contemplated by the Merger Agreement, including the
approval, execution, delivery and performance of the TorreyPines Voting Agreements (as such term is defined in the Merger Agreement). In addition, notwithstanding the foregoing, none of Raptor Pharmaceuticals, Inc., a Delaware corporation
(“Raptor”), or any Affiliate or Associate thereof, or any stockholder of Raptor shall become an “Acquiring Person” as a result of (i) the approval, execution, delivery or performance of that certain Agreement and Plan of
Merger and Reorganization dated as of July [    ], 2009 (as the same may be amended from time to time, the “Raptor Merger Agreement”), by and among the Company, Raptor and ECP Acquisition, Inc., including the approval,
execution, delivery or performance of any amendments thereto, (ii) the consummation of the Merger (as such term is defined in the Raptor Merger Agreement), (iii) the issuance of Common Stock pursuant to the Raptor Merger Agreement,
(iv) the announcement of the Raptor Merger Agreement or the Merger, or (v) the consummation of any other transaction contemplated by the Raptor Merger Agreement, including the approval, execution, delivery and performance of the Raptor
Voting Agreements (as such term is defined in the Raptor Merger Agreement).” 

 2. Section 1(i) of the Rights Agreement, which sets forth the definition of “Stock Acquisition
Date,” is hereby amended by adding as the final sentence thereto the following: 
 “Notwithstanding anything in the Agreement to
the contrary, no Stock Acquisition Date shall be deemed to have occurred in connection with or as a result of (i) the approval, execution, delivery or performance of the Raptor Merger Agreement, (ii) the consummation of the Merger,
(iii) the issuance of Common Stock pursuant to the Raptor Merger Agreement, (iv) the announcement of the Raptor Merger Agreement or the Merger, or (v) the consummation of any other transaction contemplated by the Raptor Merger
Agreement, including the approval, execution and delivery of the Raptor Voting Agreements.” 
 3. Section 1(i) of the Rights
Agreement is hereby amended by adding as the final sentence thereto the following: 
 “Notwithstanding anything in the Agreement to the
contrary, no Distribution Date shall be deemed to have occurred in connection with or as a result of (i) the approval, execution, delivery or performance of the Raptor Merger Agreement, (ii) the consummation of the Merger, (iii) the
issuance of Common Stock pursuant to the Raptor Merger Agreement, (iv) the announcement of the Raptor Merger Agreement or the Merger, or (v) the consummation of any other transaction contemplated by the Raptor Merger Agreement, including
the approval, execution and delivery of the Raptor Voting Agreements.” 
 4. Section 11(a)(ii) of the Rights Agreement is hereby
amended by adding as the final sentence thereto the following: 
 “Notwithstanding anything in the Agreement to the contrary, no event
described in this Section 11(a)(ii) shall be deemed to have occurred solely as a result of (i) the approval, execution, delivery or performance of the Raptor Merger Agreement, (ii) the consummation of the Merger, (iii) the
issuance of Common Stock pursuant to the Raptor Merger Agreement, (iv) the announcement of the Raptor Merger Agreement or the Merger, or (v) the consummation of any other transaction contemplated by the Raptor Merger Agreement, including
the approval, execution and delivery of the Raptor Voting Agreements.” 
 5. Section 13(a) of the Rights Agreement is hereby
amended by adding as the final sentence thereto the following: 
 “Notwithstanding anything in the Agreement to the contrary, none of
the events described in clauses (x) through (z) of the first sentence of Section 13(a) shall be deemed to have occurred solely as a result of (i) the approval, execution, delivery or performance of the Raptor Merger Agreement,
(ii) the consummation of the Merger, (iii) the issuance of Common Stock pursuant to the Raptor Merger Agreement, (iv) the announcement of the Raptor Merger Agreement or the Merger, or (v) the consummation of any other transaction
contemplated by the Raptor Merger Agreement, including the approval, execution and delivery of the Raptor Voting Agreements.” 
 6.
Except as expressly amended hereby, the Rights Agreement remains in full force and effect in accordance with its terms. By executing this Amendment below, the Company certifies that this Amendment has been executed and delivered in compliance

 
with the terms of Section 27 of the Rights Agreement. This Amendment shall become effective following execution and delivery of the Raptor Merger
Agreement. Upon any termination of the Raptor Merger Agreement pursuant to the terms of Section 7 thereof, or if the Raptor Merger Agreement is not executed or delivered, this Amendment shall be cancelled and shall be of no further force or
effect. 
 4. All acts and things necessary to make this Amendment a valid agreement according to its terms have been done and performed, and
the execution and delivery of this Amendment by the Company and the Rights Agent have been in all respects authorized by the Company and the Rights Agent. 
 5. This Amendment to the Rights Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. 
 6. This Amendment to the Rights Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed an original, and all such counterparts shall together
constitute but one and the same instrument. 
 7. Except as expressly set forth herein, this Amendment to the Rights Agreement shall not
by implication or otherwise alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Rights Agreement, all of which are ratified and affirmed in all respects and shall continue in
full force and effect. 
 8. If any term, provision, covenant or restriction of this Amendment is held by a court of competent
jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and effect. 
 9. Capitalized terms used herein but not defined shall have the meanings given to them in the Rights Agreement. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Rights Agreement to be duly
executed as of the day and year first above written. 
  

			
	TorreyPines Therapeuctics, Inc.
		
	By: 	 	 /s/    Paul Schneider

	Name:	 	Paul Schneider
	Title:	 	Vice President and General Counsel
	
	 American Stock Transfer and Trust Company,
 as Rights Agent

		
	By:	 	 /s/    Barry S. Rosenthal

	Name:	 	Barry S. Rosenthal
	Title:	 	Vice PresidentSecond Amendment and Restated Employment - Evelyn Graham

 Exhibit 10.1 
 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
 This Second Amended and Restated Employment
Agreement (the “Agreement”), by and between TPTX, Inc., a Delaware corporation (the “Company”), Evelyn Graham (the “Employee”) and for purposes of its obligations solely which are set forth in Section 2.2,
TorreyPines Therapeutics, Inc., a Delaware corporation (“TorreyPines”), is entered into as of July 27, 2009 and shall become effective automatically and without further action by any Party hereto immediately after the Effective Time
of the Merger Agreement (as defined below) (provided that (i) Employee is employed by the Company at the Effective Time (as defined in the Merger Agreement) and (ii) Employee has been continuously employed by the Company pursuant to the
Prior Agreements (as defined below) from the date of this Agreement to the Effective Time). This Agreement shall replace and supersede all prior employment agreements between Employee and the Company and/or TorreyPines including, but not limited to,
that certain Employment Agreement entered into effective as of December 14, 2006, as amended and restated pursuant to that certain Amended and Restated Employment Agreement entered into effective as of September 1, 2008, as amended by that
certain Amendment to Employment Agreement made and entered into as of February 3, 2009 (collectively, the “Prior Agreements”). The Company, TorreyPines and the Employee are hereinafter collectively referred to as the
“Parties,” and individually referred to as a “Party.” 
 RECITALS 
 A. The Company and/or the Company’s parent, TorreyPines, and Employee previously entered into the Prior Agreements and desire to amend and restate
the Prior Agreements in their entirety as set forth herein, effective as of the Effective Time, in order to induce the Company and Raptor Pharmaceuticals, Corp. (“Raptor”) to consummate the transactions contemplated by that certain
Agreement and Plan of Merger and Reorganization, dated July 27, 2009 (the “Merger Agreement”). 
 B. The Company desires to
retain the Employee’s experience, skills, abilities, background and knowledge and is willing to engage the Employee’s services on the terms and conditions set forth in this Agreement. 
 C. The Employee has agreed to reduce the severance payment obligation set forth in the Prior Agreements and desires to be in the employ of the Company
and is willing to accept such employment on the terms and conditions set forth in this Agreement. 
 AGREEMENT 
 In consideration of the foregoing Recitals and the mutual promises and covenants herein contained, and for other good and valuable consideration, the
Parties, intending to be legally bound, agree as follows: 
 1. EMPLOYMENT 
 1.1 Title. The Employee shall serve as the Company’s President The Employee shall report solely and directly to the board of directors of the
Company (the “Board”). 
  

 1 

 1.2 Obligations. Employee is required to read, review and observe all of the Company’s
policies, procedures, rules and regulations in effect from time to time. 
 1.3 Term. This Agreement and the Employee’s
employment shall terminate on the earlier of (i) February 28, 2010 or (ii) such other date this Agreement and Employee’s employment is terminated under Section 3 (the “Expiration Date”). Except as set forth in
Section 3.10, upon the Expiration Date, all of the Company’s obligations and each such Party’s respective rights under this Agreement shall immediately lapse. 
 2. COMPENSATION OF THE EMPLOYEE 
 2.1 Base Salary. The Company shall pay the Employee a base
salary of Twenty-Nine Thousand One Hundred Sixty-Seven Dollars ($29,167) per month, payable in regular periodic payments in accordance with Company policy. Such base salary shall be prorated for any partial month of employment on the basis of a
31-day month. 
 2.2 Additional Compensation. If, following the Effective Time and prior to February 28, 2010, the Company
(i) sells to a Buyer (as defined below) any equity securities of the Company and the proceeds from such Sale (as defined below) are used primarily for the development of the Company’s product designated NGX426, (ii) completes a Change
of Control Transaction or (iii) enters into a partnership, option, or similar arrangement (any transaction described in clauses (i), (ii) or (iii), the “Sale”), and the Sale described in clauses (i), (ii) or (iii) is
approved by the Board and is for aggregate cash consideration (net of all costs and expenses associated with the Sale) received by the Company on or before February 28, 2010 of not less than $10 million, then promptly following the closing of
the Sale, (A) the Company shall pay to the Employee an amount equal to (x) 3.0% of the aggregate cash consideration (net of all costs and expenses associated with the Sale) received by the Company in the Sale multiplied by (y) 41%,
and (B) TorreyPines shall pay to the Employee an amount equal to (x) 2.0% of the aggregate cash consideration (net of all costs and expenses associated with the Sale) received by the Company in the Sale multiplied by (y) 41%. As used
herein, “Buyer” means any third party other than TorreyPines or any of its subsidiaries. The amount described in clause (A) of this Section 2.2 shall be payable in cash by the delivery of a Company check to the Employee, and the
amount described in clause (B) of this Section 2.2 shall be payable in shares of the TorreyPines’ common stock. The number of shares of TorreyPines’ common stock issuable pursuant to clause (B) of this Section 2.2 shall
equal the amount described in clause (B) of this Section 2.2, divided by the Per Share Price. As used herein, the “Per Share Price” means the average closing sales price of the TorreyPines’ common stock on the NASDAQ Capital
Market for the five (5) consecutive trading days immediately prior to the date of the issuance of TorreyPines’ common stock pursuant to this Section 2.2. No fractional shares of TorreyPines’ common stock shall be issued pursuant
to this Section 2.2. In lieu of fractional shares, Employee shall receive, without interest, an amount in cash (rounded to the nearest whole cent) determined by multiplying such fraction by the Per Share Price. The Parties understand,
acknowledge and agree that any TorreyPines’ common stock issued pursuant to this Section 2.2 shall not, when issued, be registered under the Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction. As
used herein “Change of Control Transaction” means (i) a merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer,
exchange offer or 

  

 2 

 
other similar transaction as a result of which either (A) the Company’s stockholders immediately prior to such transaction in the aggregate cease
to own directly or indirectly at least 50% of the voting securities of the entity surviving or resulting from such transaction (or the ultimate parent entity thereof) or (B) in which a Person or “group” (as defined in the Exchange Act
and the rules promulgated thereunder) directly acquires beneficial or record ownership of securities representing 50% or more of the Company’s capital stock or (ii) a sale, lease, exchange, transfer, license or disposition of any business
or other disposition of at least 50% of the assets (on a book value or fair market value basis) of the Company, taken as a whole, as applicable, in a single transaction or a series of related transactions. 
 2.3 Employment Taxes. All of the Employee’s compensation (in any form) shall be subject to all required withholding taxes, employment taxes
and other deductions required by law. 
 2.4 Benefits. The Employee shall, in accordance with Company policy and the terms of the
applicable plan documents, be eligible to participate in health benefits under any health benefit plan or arrangement which may be in effect from time to time and made available to the Company’s employees. The Employee shall not be eligible for
any paid vacation. 
 2.5 Annual Incentive Bonus. Employee agrees that Employee shall not be entitled to any bonus with respect to any
period of time, whether prior to, on, or after the Effective Time. 
 3. TERMINATION 
 3.1 Termination. The Employee’s employment with the Company may be terminated under the conditions set forth below. The Employee’s
employment by the Company shall be “at will.” 
 3.2 Termination for Death. The Employee’s employment with the Company
shall terminate effective upon the date of the Employee’s death. 
 3.3 Termination by the Company For Any Reason or No Reason.
The Company may terminate the Employee’s employment under this Agreement at any time, for any or no reason and with or without cause or advance notice and such termination shall not be deemed a breach by the Company of any term of this
Agreement or any other duty or obligation, expressed or implied, which the Company may owe to Employee pursuant to any principle or provision of law. This is the full and complete agreement between the Employee and the Company on this term. Although
the Employee’s duties, title, compensation and benefits may change, the “at will” nature of the Employee’s employment relationship with the Company may only be modified in an express written agreement signed by the Employee and a
member of the Board on behalf of the Company. 
 3.4 Termination by Mutual Agreement of the Parties. The Employee’s employment
pursuant to this Agreement may be terminated at any time upon the mutual written agreement of the Parties. Any such termination of employment shall have the consequences specified in such writing. 
  

 3 

 3.5 Termination by the Employee. The Employee shall have the right to resign or terminate the
Employee’s employment at any time, with or without cause or notice. 
 3.6 Compensation Upon Termination. 
 3.6.1 Termination. Upon Employee’s termination for whatever reason, the Company shall pay: 
 3.6.1.1 Employee’s base salary earned through the date of such termination or resignation, less standard deductions and withholdings. Except as
specifically provided in subsections 3.6.1.2 and 3.6.1.3, below, the Company shall thereafter have no further obligation to the Employee under this Agreement. 
 3.6.1.2 assuming the Employee timely and accurately elects to continue Employee’s health insurance benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company shall
pay the COBRA premiums for the Employee and Employee’s qualified beneficiaries under any Company-sponsored group health plan that the Company does not treat as self insured (e.g., it will not pay the COBRA premiums with respect to any Flexible
Spending Account), until the earliest of (i) August 31, 2010, (ii) the expiration of the Employee’s continuation coverage under COBRA and any applicable state COBRA-like statute that provides mandated continuation coverage or
(iii) the date the Employee becomes eligible for health insurance benefits of a subsequent employer. Employee agrees to immediately notify the Company in writing of any such eligibility. 
 3.6.1.3 Employee’s base salary during the period following the termination or resignation of the Employee for a period between the date of
employment termination and February 28, 2010. Such severance payments shall be subject to standard deductions and withholdings and paid in accordance with the Company’s regular payroll policies and practices. For purposes of calculating
the amount to be paid pursuant this Section 3.6.1.3 the Company shall use the Employee’s base salary in effect on the date of such termination or resignation. 
 3.6.2 Release and Agreement Release. Notwithstanding the foregoing, the Employee shall not receive any of the additional compensation, severance payments or benefits set forth under Sections 2.2, 3.6.1.1,
3.6.1.2 or 3.6.1.3, unless within the time period set forth therein, but in no event later than forty-five (45) days following termination of employment, the Employee furnishes the Company with a waiver and release of claims in a form
acceptable to the Parties and substantially as attached hereto as Exhibit A, including such changes as may be made by the Board as necessary to comply with applicable laws (the “Release”), and such Release becomes effective in
accordance with its terms. Notwithstanding anything herein to the contrary, the Employee acknowledges, understands and agrees that the Company shall not be obligated to pay, and the Employee shall not receive, any of the base salary payments,
additional compensation, severance payments or benefits set forth under Sections 2.1, 2.2, 3.6.1.1, 3.6.1.2 or 3.6.1.3, if that certain Release and Waiver of Claims executed by the Employee in favor of the Company and TorreyPines and other released
parties as described therein, a form of which is attached to the Merger Agreement as Exhibit E thereto (the “Agreement Release”), is timely revoked by the Employee as permitted therein. Notwithstanding the foregoing, under no circumstances
shall the foregoing Release or Agreement Release or the conditions precedent to the Company’s obligations hereunder affect the effectiveness of this Agreement (or the cancellation of the Prior Agreements) as set forth in preamble to this
Agreement. 
  

 4 

 3.7 Parachute Payments. Anything in this Agreement to the contrary notwithstanding, if any payment
or benefit the Employee would receive from the Company or an affiliate of the Company pursuant to this Agreement or otherwise (a “Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G
of the Internal Revenue Code of 1986, as amended (the “Code”), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the
Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion of the Payment, up to and
including the total Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the
Employee’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute
payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order: reduction of cash payments; reduction of employee benefits. 
 The Company shall appoint a nationally recognized independent accounting firm to make the determinations required hereunder. The Company shall bear all
expenses with respect to the determinations by such accounting firm required to be made hereunder. 
 The accounting firm engaged to make the
determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and the Employee within fifteen (15) calendar days after the date on which the Employee’s right to a Payment is
triggered (if requested at that time by the Company or the Employee) or such other time as requested by the Company or the Employee. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after
the application of the Reduced Amount, it shall furnish the Company and the Employee with an opinion reasonably acceptable to the Employee that no Excise Tax will be imposed with respect to such Payment. The Company shall be entitled to rely upon
the accounting firm’s determinations, which shall be final and binding on all persons. 
 3.8 Exclusive Remedy. The rights,
remedies and payments set forth in this Section 4 shall be the exclusive rights, remedies and payments available to the Employee upon termination of this Agreement and the Employee’s employment hereunder. Such rights remedies and payments
shall supersede and replace any and all rights and remedies under state or federal law. To the extent permitted by applicable laws, the Company may deduct any amounts the Employee owes the Company at the time of the Employee’s termination of
employment from any severance payments. 
 3.9 Application of Section 409A. Notwithstanding anything to the contrary set forth
herein, any payments and benefits provided under this Agreement (the “Severance Benefits”) that constitute “deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”) and the regulations and other guidance thereunder and any state law of 

  

 5 

 
similar effect (collectively “Section 409A”) shall not commence in connection with Employee’s termination of employment unless and until
Employee has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”). 
 It is intended that each installment of the Severance Benefits payments provided for in this Agreement is a separate “payment” for purposes of
Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of
Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). 
 However, if the Company
(or, if applicable, the successor entity thereto) determines that the Severance Benefits, or a portion thereof, constitute “deferred compensation” under Section 409A and Employee is, on the termination of Employee’s service, a
“specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, to the extent necessary to avoid the imposition of any additional tax or income recognition
under Section 409A prior to actual payment to the Employee, the timing of the Severance Benefit payments that constitute “deferred compensation” under Section 409A shall be delayed until the earlier to occur of: (i) the date
that is six months and one day after Employee’s Separation From Service or (ii) the date of Employee’s death (such applicable date, the “Specified Employee Initial Payment Date”). On the Specified Employee Initial Payment
Date, the Company (or the successor entity thereto, as applicable) shall (A) pay to Employee a lump sum amount equal to the sum of the Severance Benefit payments that Employee would otherwise have received through the Specified Employee Initial
Payment Date if the commencement of the payment of the Severance Benefits had not been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set
forth in this Agreement. 
 Except to the extent that payments are delayed until the Specified Employee Initial Payment Date pursuant to the
preceding paragraph, on the first regular payroll pay day following the date the Release becomes effective and irrevocable, the Company will pay Employee the Severance Benefits Employee would otherwise have received under the Agreement on or prior
to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance Benefits being paid as originally scheduled. All amounts payable under the Agreement will be subject to standard payroll taxes
and deductions. 
 It is the intent of this Agreement to comply with the requirements of Section 409A so that none of the Severance
Benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and the Employee agree to work together in good faith to consider
amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition under Section 409A prior to actual payment to the Employee (provided
that no such amendment shall materially reduce the benefits provided hereunder). 
  

 6 

 3.10 Survival of Certain Sections. Sections 2.3, 3.6.1.2, 3.6.1.3, 3.6.2, 3.7, 3.8, 3.9, 3.10 and
4 – 16 of this Agreement shall survive the termination of this Agreement, and Section 2.2 shall survive the termination of this Agreement in accordance with its terms. 
 4. CONFIDENTIAL AND PROPRIETARY INFORMATION; NONSOLICITATION 
 4.1 Proprietary Information and
Inventions Agreement. As a condition of employment, the Employee agrees to execute and abide by the Proprietary Information and Inventions Agreement attached hereto as Exhibit B. 
 4.2 Non-Solicitation. During the Employee’s employment with the Company and the Benefit Severance Period and for one (1) year after the
termination of such periods, the Employee agrees that in order to protect the confidential and proprietary information of the Company, TorreyPines and their respective subsidiaries from unauthorized use, the Employee shall not, either directly or
through others, solicit or attempt to solicit any employee, consultant or independent contractor of the Company, TorreyPines or any of their respective subsidiaries to terminate his or her relationship with the Company or TorreyPines (or the
applicable subsidiary) in order to become an employee, consultant or independent contractor to or for any other person or business entity. 
 4.3 Return of Company Property. Employee acknowledges that, upon termination of Employee’s employment for any reason whatsoever (or at any time on the Company’s request), Employee will promptly deliver to the Company or
surrender to the Company’s authorized representative all property of the Company or any of its affiliates (the “Company Group”), including, without limitation, all documents and other materials (and all copies thereof) relating to the
Company Group’s business, all identification and access cards, all contact lists and third party business cards however and wherever preserved, and any equipment provided by any entity in the Company Group, including, without limitation,
computers, telephones, personal digital assistants, memory cards and similar devices that Employee possesses or has in Employee’s custody or under Employee’s control. Employee will cooperate with the Company by participating in interviews
to share any knowledge Employee may have regarding the Company Group’s intellectual or other property with personnel designated by the Company. 
 5.
ASSIGNMENT AND BINDING EFFECT 
 This Agreement shall be binding upon and inure to the benefit of the Employee and the Employee’s
heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the Employee’s duties under this Agreement, neither this Agreement nor any rights or obligations under
this Agreement shall be assignable by the Employee. This Agreement shall be binding upon and inure to the benefit of the Company, TorreyPines and their respective successors, assigns and legal representatives. 
 6. CHOICE OF LAW 
 This Agreement is made and intended
to be performed primarily within the state of California. This Agreement shall be construed and interpreted in accordance with the internal laws of the state of California (without giving effect to principles of conflicts of law). 
  

 7 

 7. INTEGRATION 
 Except as may otherwise be provided herein, this Agreement, including Exhibit A and Exhibit B, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of the
Employee’s employment and the termination of Employee’s employment, and supersedes all prior and contemporaneous oral and written employment agreements or arrangements between the Parties, including but not limited to the Prior Agreements.
To the extent this Agreement conflicts with the Proprietary Information and Inventions Agreement attached as Exhibit B, the Proprietary Information and Inventions Agreement controls. 
 8. AMENDMENT 
 This Agreement cannot be amended or
modified except by a written agreement signed by the Employee and a member of the Board on behalf of the Company. 
 9. WAIVER 
 No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom
the waiver is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. 
 10. SEVERABILITY 
 The finding by a court of competent
jurisdiction or other authorized body of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. The invalid or unenforceable term or
provision shall be modified or replaced with a valid and enforceable term or provision which most accurately represents the Parties’ intention with respect to the invalid or unenforceable term or provision. 
 11. INTERPRETATION; CONSTRUCTION 
 The headings set
forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. The Employee has been encouraged to consult with, and has consulted with, Employee’s own independent counsel and tax advisors
with respect to the terms of this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any
ambiguities are to be resolved against the drafting Party shall not be employed in the interpretation of this Agreement. 
 12. REPRESENTATIONS AND
WARRANTIES 
 The Employee represents and warrants that the Employee is not restricted or prohibited, contractually or otherwise, from
entering into and performing each of the terms and covenants contained in this Agreement, and that the Employee’s execution and performance of this Agreement shall not violate or breach any other agreements between the Employee and any other
person or entity. 
  

 8 

 13. COUNTERPARTS 
 This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall constitute one and the same instrument. 
 14. ARBITRATION 
 To ensure the rapid and economical
resolution of disputes that may arise in connection with the Employee’s employment with the Company, the Employee, the Company and TorreyPines agree that any and all disputes, claims, or causes of action, in law or equity, arising from or
relating to Employee’s employment, or the termination of that employment, or this Agreement, will be resolved, to the fullest extent permitted by law, by final binding arbitration in San Francisco, California conducted by the Judicial
Arbitration and Mediation Services (“JAMS”), or its successors, under the then current rules of JAMS for employment disputes; provided that the arbitrator shall: (a) have the authority to compel adequate discovery for the resolution
of the dispute and to award such relief as would otherwise be permitted by law and (b) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award. Each of the Employee,
the Company and TorreyPines shall be entitled to all rights and remedies that any of the Employee, the Company or TorreyPines would be entitled to pursue in a court of law. The Company shall pay all administrative fees associated with the
arbitration and the fees of the arbitrator. Nothing in this Agreement is intended to prevent any of the Employee, the Company or TorreyPines from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration. 
 15. ALL TERMS MATERIAL 
 Employee’s failure to comply with any of the terms of this Agreement shall constitute a material breach of this Agreement. 
 16. TRADE
SECRETS OF OTHERS 
 It is the understanding of both the Company and the Employee that the Employee shall not divulge to the Company
and/or its subsidiaries any confidential information or trade secrets belonging to others, including the Employee’s former employers (not including for this purpose TorreyPines), nor shall the Company and/or its subsidiaries seek to elicit from
the Employee any such information. Consistent with the foregoing, the Employee shall not provide to the Company and/or its subsidiaries, and the Company and/or its subsidiaries shall not request, any documents or copies of documents containing such
information. 
  

 9 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first shown above.

  

			
	TPTX, Inc.,
	a Delaware corporation
		
	By:	 	 /s/ Craig Johnson

		 	 Craig Johnson

		 	 Chief Financial Officer

	
	TorreyPines Therapeutics, Inc.,
	a Delaware corporation
	(for the purpose of its obligations which are solely set forth in Section 2.2)
		
	By:	 	 /s/ Craig Johnson

		 	 Craig Johnson

		 	 Chief Financial Officer

	
	Employee
		
	By:	 	 /s/ Evelyn Graham

		 	Evelyn Graham

 [Signature Page to Employment Agreement] 

 EXHIBIT A 
 RELEASE AND WAIVER OF CLAIMS 
 In consideration of the payments and other benefits set forth in
Section 3.6.1.1, 3.6.1.2, and 3.6.1.3 of the Second Amended and Restated Employment Agreement dated July 27, 2009 (the “Employment Agreement”), to which this form is attached, I, Evelyn Graham, hereby furnish TPTX, Inc., a
Delaware corporation (the “Company”) and TorreyPines Therapeutics, Inc., a Delaware corporation (“TorreyPines”), with the following release and waiver (“Release and Waiver”): 
 In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, except with respect to claims
that the law does not permit me to waive by signing this Agreement, I hereby generally and completely release each of the Company and TorreyPines, and each of their respective directors, officers, employees, shareholders, partners, agents,
attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all claims, liabilities and obligations, both known and unknown, that arise out of
or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release and Waiver. This general release includes, but is not limited to: (1) all claims arising out of or in any way related to my employment
with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company and/or TorreyPines, including, but not limited to, salary, bonuses, commissions, vacation pay, expense
reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company and/or TorreyPines; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (4) all tort claims, including, but not limited to, claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including,
but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age
Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). 
 I also acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or
her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any
law of any jurisdiction of similar effect with respect to any claims I may have against any of the Released Parties. 
 I acknowledge that,
among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was
already entitled as an executive of the Company. I am hereby advised, as required by the Older Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this
Release and Waiver is executed; (b) I should consult with an attorney prior to executing this Release and Waiver; (c) I have 

  

 i 

 
twenty-one (21) days in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier);
(d) I have seven (7) days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver by giving written notification of such revocation to the Company and TorreyPines within such time period; and
(e) this Release and Waiver shall not become effective if I properly revoked this Release and Waiver in accordance with clause (d) hereof. 
 I acknowledge and agree to my continuing obligations under my Proprietary Information and Inventions Agreement, a copy of which is attached to the Employment Agreement. I understand and agree that my right to the
severance pay I am receiving in exchange for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance with my Proprietary Information and Inventions Agreement. I hereby represent that I have not transferred or
assigned any claim that I may have against any of the Released Parties. I represent that I have not filed any claims against any of the Released Parties. 
 This Release and Waiver, including any referenced documents, constitutes the complete, final and exclusive embodiment of the entire agreement between the Company, TorreyPines and me with regard to the subject matter
hereof. I am not relying on any promise or representation by the Company or TorreyPines that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and a member of the Board on behalf of the
Company and a member of the board of directors of TorreyPines. 
  

					
		 		  	  

	Date:                     	 		  	Evelyn Graham

  

 ii 

 EXHIBIT B 
 PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT 
  

 i

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]